TY - JOUR
T1 - Global Consultation on Cancer Staging
T2 - promoting consistent understanding and use
AU - Brierley, James
AU - O’Sullivan, Brian
AU - Asamura, Hisao
AU - Byrd, David
AU - Huang, Shao Hui
AU - Lee, Anne
AU - Piñeros, Marion
AU - Mason, Malcolm
AU - Moraes, Fabio Y.
AU - Rösler, Wiebke
AU - Rous, Brian
AU - Torode, Julie
AU - van Krieken, J. Han
AU - Gospodarowicz, Mary
N1 - Funding Information:
Funding for this work was provided (in part) by the US National Cancer Institute and by the US Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the US Government.
Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Disease burden is the most important determinant of survival in patients with cancer. This domain, reflected by the cancer stage and codified using the tumour-node-metastasis (TNM) classification, is a fundamental determinant of prognosis. Accurate and consistent tumour classification is required for the development and use of treatment guidelines and to enable clinical research (including clinical trials), cancer surveillance and control. Furthermore, knowledge of the extent and stage of disease is frequently important in the context of translational studies. Attempts to include additional prognostic factors in staging classifications, in order to facilitate a more accurate determination of prognosis, are often made with a lack of knowledge and understanding and are one of the main causes of the inconsistent use of terms and definitions. This effect has resulted in uncertainty and confusion, thus limiting the utility of the TNM classification. In this Position paper, we provide a consensus on the optimal use and terminology for cancer staging that emerged from a consultation process involving representatives of several major international organizations involved in cancer classification. The consultation involved several steps: a focused literature review; a stakeholder survey; and a consultation meeting. This aim of this Position paper is to provide a consensus that should guide the use of staging terminology and secure the classification of anatomical disease extent as a distinct aspect of cancer classification.
AB - Disease burden is the most important determinant of survival in patients with cancer. This domain, reflected by the cancer stage and codified using the tumour-node-metastasis (TNM) classification, is a fundamental determinant of prognosis. Accurate and consistent tumour classification is required for the development and use of treatment guidelines and to enable clinical research (including clinical trials), cancer surveillance and control. Furthermore, knowledge of the extent and stage of disease is frequently important in the context of translational studies. Attempts to include additional prognostic factors in staging classifications, in order to facilitate a more accurate determination of prognosis, are often made with a lack of knowledge and understanding and are one of the main causes of the inconsistent use of terms and definitions. This effect has resulted in uncertainty and confusion, thus limiting the utility of the TNM classification. In this Position paper, we provide a consensus on the optimal use and terminology for cancer staging that emerged from a consultation process involving representatives of several major international organizations involved in cancer classification. The consultation involved several steps: a focused literature review; a stakeholder survey; and a consultation meeting. This aim of this Position paper is to provide a consensus that should guide the use of staging terminology and secure the classification of anatomical disease extent as a distinct aspect of cancer classification.
UR - http://www.scopus.com/inward/record.url?scp=85070416981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070416981&partnerID=8YFLogxK
U2 - 10.1038/s41571-019-0253-x
DO - 10.1038/s41571-019-0253-x
M3 - Article
C2 - 31388125
AN - SCOPUS:85070416981
SN - 1759-4774
VL - 16
SP - 763
EP - 771
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 12
ER -